Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Garadacimab→

Garadacimab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not available
Molecular formula
C6382H9846N1686O1994S42
Molecular weight
~143700 g/mol
Drug class
Activated factor XII (FXIIa) inhibitorfully human monoclonal antibody
Mechanism of action
Binds the catalytic domain of activated factor XII (FXIIa and βFXIIa) and inhibits its activity. This reduces activation of prekallikrein to kallikrein and subsequent bradykinin generation in the contact activation/kallikrein–kinin pathway.
Indications / reported uses
  • Routine prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and paediatric patients aged 12 years and older under the US ANDEMBRY indication (approved 16 June 2025); not for treatment of an acute HAE attack

Sources: US FDA prescribing information — ANDEMBRY (garadacimab-gxii) · FDA Orphan Drug database — Garadacimab marketing approval and indication · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Activated factor XII (FXIIa) inhibitor; fully human monoclonal antibody

Mechanism of action

Binds the catalytic domain of activated factor XII (FXIIa and βFXIIa) and inhibits its activity. This reduces activation of prekallikrein to kallikrein and subsequent bradykinin generation in the contact activation/kallikrein–kinin pathway.

General use cases

  • Routine prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and paediatric patients aged 12 years and older under the US ANDEMBRY indication (approved 16 June 2025); not for treatment of an acute HAE attack

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Garadacimab Environmental Risk Assessment (ERA) (the Garadacimab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.